Gain Therapeutics Inc [GANX] stock is trading at $1.97, down -5.29%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The GANX shares have gain 2.60% over the last week, with a monthly amount glided 14.53%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Gain Therapeutics Inc [NASDAQ: GANX] stock has seen the most recent analyst activity on March 07, 2025, when Scotiabank initiated its Sector Outperform rating and assigned the stock a price target of $12. Previously, ROTH MKM started tracking the stock with Buy rating on December 06, 2024, and set its price target to $7. Oppenheimer started tracking the stock assigning a Outperform rating and suggested a price target of $30 on April 12, 2021. BTIG Research initiated its recommendation with a Buy and recommended $30 as its price target on April 12, 2021.
Gain Therapeutics Inc [GANX] stock has fluctuated between $1.41 and $3.19 over the past year. Currently, Wall Street analysts expect the stock to reach $7 within the next 12 months. Gain Therapeutics Inc [NASDAQ: GANX] shares were valued at $1.97 at the most recent close of the market. An investor can expect a potential return of 255.33% based on the average GANX price forecast.
Analyzing the GANX fundamentals
Gross Profit Margin for this corporation currently stands at -0.77% with Operating Profit Margin at -209.73%, Pretax Profit Margin comes in at -216.87%, and Net Profit Margin reading is -226.08%. To continue investigating profitability, this company’s Return on Assets is posted at -1.89, Equity is -2.89 and Total Capital is -3.72. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.06.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
For context, Gain Therapeutics Inc’s Current Ratio is 1.79. Also, the Quick Ratio is 1.79, while the Cash Ratio stands at 1.29.
